TGF-β signaling in the tumor metabolic microenvironment and targeted therapies

X Shi, J Yang, S Deng, H Xu, D Wu, Q Zeng… - Journal of Hematology & …, 2022 - Springer
Transforming growth factor-β (TGF-β) signaling has a paradoxical role in cancer
progression, and it acts as a tumor suppressor in the early stages but a tumor promoter in …

The redox role of G6PD in cell growth, cell death, and cancer

HC Yang, YH Wu, WC Yen, HY Liu, TL Hwang, A Stern… - Cells, 2019 - mdpi.com
The generation of reducing equivalent NADPH via glucose-6-phosphate dehydrogenase
(G6PD) is critical for the maintenance of redox homeostasis and reductive biosynthesis in …

Identification of the prognostic value of ferroptosis-related gene signature in breast cancer patients

D Wang, G Wei, J Ma, S Cheng, L Jia, X Song… - BMC cancer, 2021 - Springer
Background Breast cancer (BRCA) is a malignant tumor with high morbidity and mortality,
which is a threat to women's health worldwide. Ferroptosis is closely related to the …

[HTML][HTML] The role of autophagy in resistance to targeted therapies

L Mele, V Del Vecchio, D Liccardo, C Prisco… - Cancer Treatment …, 2020 - Elsevier
Autophagy is a self-degradative cellular process, involved in stress response such as
starvation, hypoxia, and oxidative stress. This mechanism balances macro-molecule …

Extracellular Vesicle-Mediated Transfer of LncRNA IGFL2-AS1 Confers Sunitinib Resistance in Renal Cell Carcinoma

Y Pan, X Lu, G Shu, J Cen, J Lu, M Zhou, K Huang… - Cancer research, 2023 - AACR
Sunitinib resistance remains a serious challenge to the treatment of advanced and
metastatic renal cell carcinoma (RCC), yet the mechanisms underlying this resistance are …

Metabolic reprogramming in cancer cells: emerging molecular mechanisms and novel therapeutic approaches

C Navarro, Á Ortega, R Santeliz, B Garrido, M Chacín… - Pharmaceutics, 2022 - mdpi.com
The constant changes in cancer cell bioenergetics are widely known as metabolic
reprogramming. Reprogramming is a process mediated by multiple factors, including …

The pentose phosphate pathway in cancer: regulation and therapeutic opportunities

N Ghanem, C El-Baba, K Araji, R El-Khoury, J Usta… - Chemotherapy, 2021 - karger.com
Background: Tumorigenesis is associated with deregulation of nutritional requirements,
intermediary metabolites production, and microenvironment interactions. Unlike their normal …

The multiple roles of glucose-6-phosphate dehydrogenase in tumorigenesis and cancer chemoresistance

J Song, H Sun, S Zhang, C Shan - Life, 2022 - mdpi.com
The pentose phosphate pathway (PPP) is a branch from glycolysis that begins from glucose-
6-phosphate (G6P) and ends up with fructose-6-phosphate (F6P) and glyceraldehyde-3 …

Recent findings in the regulation of G6PD and its role in diseases

Q Meng, Y Zhang, S Hao, H Sun, B Liu… - Frontiers in …, 2022 - frontiersin.org
Glucose-6-phosphate dehydrogenase (G6PD) is the only rate-limiting enzyme in the
pentose phosphate pathway (PPP). Rapidly proliferating cells require metabolites from PPP …

Polydatin: pharmacological mechanisms, therapeutic targets, biological activities, and health benefits

A Karami, S Fakhri, L Kooshki, H Khan - Molecules, 2022 - mdpi.com
Polydatin is a natural potent stilbenoid polyphenol and a resveratrol derivative with
improved bioavailability. Polydatin possesses potential biological activities predominantly …